好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Baseline Perfusion Imaging Collateral Scores Predict Infarct Growth in DEFUSE 3
Cerebrovascular Disease and Interventional Neurology
S47 - Stroke Outcomes and Recurrence (2:28 PM-2:39 PM)
009

High rCBV within the ischemic lesion and a low HIR predict good collateral vessel status and correlate with infarct growth and functional outcome in early window patients with large vessel anterior circulation occlusions.  Their performance in predicting clinical and radiologic outcome has not been assessed in late presenting patients.

We aimed to examine whether favorable baseline hypoperfusion intensity ratio (HIR) and relative cerebral blood volume (rCBV) profiles would predict less infarct growth at 24 hours in late presenting (6-16h), non-reperfused patients in DEFUSE 3.

Non-reperfused patients in both arms of DEFUSE 3 were included.  Baseline ischemic core, Tmax >6s, and Tmax >10s perfusion volumes were calculated with RAPID software; 24h infarct volumes were manually determined from DWI or CT.  Substantial infarct growth was defined as a >25mL increase between baseline and 24h infarct volume. HIR was defined as the proportion of the Tmax >6s lesion with Tmax >10s delay; rCBV was calculated by RAPID from the mean CBV values within the Tmax >6s lesion compared to regions of normal CBV.  

Eighty-four patients were included.  ROC analysis showed that HIR >0.34 (AUC=0.68) and rCBV <0.74 (AUC=0.72) optimally predicted substantial infarct growth at 24h.  Median growth was 23.4 versus 73.2mL with the HIR threshold of 0.34 (p=0.005), and 24.3 versus 58.7mL with the rCBV threshold of 0.74 (p=0.004).  If baseline HIR and rCBV were both favorable, median growth was 21.7mL, 40.9mL if one was favorable, and 108.2mL if both were unfavorable (p=<0.001). 

Perfusion collateral scores (HIR and rCBV) forecast infarct growth in late presenting, non-reperfused ischemic stroke patients.  These parameters may be useful for guiding transfer decisions, such as need for repeat imaging on arrival to a thrombectomy center, and may help identify slow progressing patients more likely to have persistent salvageable ischemic tissue beyond 24 hours.

Authors/Disclosures
Adam MacLellan, MD, BSch
PRESENTER
No disclosure on file
Michael Mlynash No disclosure on file
No disclosure on file
No disclosure on file
Maarten G. Lansberg, MD (Stanford Stroke Center) Dr. Lansberg has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Genentech. Dr. Lansberg has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen. Dr. Lansberg has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novo Nordisk. Dr. Lansberg has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for Richard & Connor. Dr. Lansberg has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for Fraser Watson Croutch. Dr. Lansberg has received publishing royalties from a publication relating to health care.
Gregory W. Albers, MD (Stanford University) No disclosure on file